Clene is a clinical-stage biopharmaceutical company, focused on the development of various therapeutics for neurodegenerative diseases. Co. has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Co.'s lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The CLNN stock yearly return is shown above.
The yearly return on the CLNN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CLNN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|